Pyxis Oncology

Pyxis Oncology EBIT

The EBIT of Pyxis Oncology (PYXS) as of Nov 2, 2026 is -84.42 M USD. In the previous year, EBIT was -89.46 M USD — a change of -5.63% (higher).

EBIT

-84.42 MUSD

YoY

-5.63%

Last updated:

In 2025, Pyxis Oncology's EBIT was -84.42 M USD, a -5.63% increase from the -89.46 M USD EBIT recorded in the previous year.

The Pyxis Oncology EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT
Date
EBIT
Jan 1, 2024
-89.46 M USD
Jan 1, 2025
-84.42 M USD
Jan 1, 2026 (e)
-76.02 M USD
Jan 1, 2027 (e)
-70.72 M USD
Jan 1, 2028 (e)
-59.10 M USD
Jan 1, 2029 (e)
-60.43 M USD
Jan 1, 2030 (e)
-36.90 M USD
Jan 1, 2031 (e)
0.00 USD
The Pyxis Oncology EBIT history
YEAREBITYoY
est0.00USD-100.00%
est-36.90 MUSD-38.95%
est-60.43 MUSD+2.26%
est-59.10 MUSD-16.43%
est-70.72 MUSD-6.98%
est-76.02 MUSD-9.95%
-84.42 MUSD-5.63%
-89.46 MUSD+8.84%
-82.20 MUSD-33.43%
-123.48 MUSD+77.12%
-69.72 MUSD+440.69%
-12.89 MUSD+347.86%
-2.88 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Pyxis Oncology Revenue

Pyxis Oncology Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2024
16.15 M USD
-89.46 M USD
-77.33 M USD
Jan 1, 2025
13.86 M USD
-84.42 M USD
-79.62 M USD
Jan 1, 2026 (e)
21,875.00 USD
-76.02 M USD
-75.54 M USD
Jan 1, 2027 (e)
3.13 M USD
-70.72 M USD
-68.97 M USD
Jan 1, 2028 (e)
15.79 M USD
-59.10 M USD
-65.88 M USD
Jan 1, 2029 (e)
42.75 M USD
-60.43 M USD
-60.55 M USD
Jan 1, 2030 (e)
112.33 M USD
-36.90 M USD
-36.97 M USD
Jan 1, 2031 (e)
273.77 M USD
0.00 USD
11.32 M USD

Pyxis Oncology Margins

Pyxis Oncology stock margins

The Pyxis Oncology margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Pyxis Oncology. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Pyxis Oncology.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2024
97.06 %
-554.07 %
-478.95 %
Jan 1, 2025
82.77 %
-609.18 %
-574.55 %
Jan 1, 2026 (e)
82.77 %
-347,534.42 %
-345,334.49 %
Jan 1, 2027 (e)
82.77 %
-2,262.99 %
-2,207.05 %
Jan 1, 2028 (e)
82.77 %
-374.38 %
-417.36 %
Jan 1, 2029 (e)
82.77 %
-141.36 %
-141.62 %
Jan 1, 2030 (e)
82.77 %
-32.85 %
-32.91 %
Jan 1, 2031 (e)
82.77 %
0.00 %
4.14 %

Pyxis Oncology Stock analysis

What does Pyxis Oncology do? Pyxis Oncology Inc develops a multi-modality portfolio of next-generation therapeutics targeting difficult-to-treat cancers, including antibody drug conjugate (ADC) product candidate PYX-201, immuno-oncology (IO) product candidate PYX-106, and monoclonal antibody (mAb) preclinical discovery programs. The company focuses on developing these as monotherapies and in combination with other therapies to improve patient quality of life. Its ADC product PYX-201 consists of an Immunoglobulin G1 (IgG1) anti-fibronectin Extradomain-B mAb site-specifically conjugated to an auristatin derivative via a cathepsin B-cleavable linker. Pyxis Oncology is developing its product pipeline including PYX-107 as part of its portfolio. The company's revenue model is based on the development and potential future commercialization of its therapeutic candidates. Pyxis Oncology is focused on advancing its pipeline through clinical trials and regulatory approvals. The firm's product candidates are designed to address unmet medical needs in oncology, targeting specific cancer types through innovative mechanisms such as ADC and IO approaches. The company's portfolio includes PYX-201, PYX-106, and PYX-107 as key therapeutic candidates in various stages of development. Pyxis Oncology Inc is a biopharmaceutical company that develops therapeutics for difficult-to-treat cancers. Its product candidates include PYX-201, PYX-106, and PYX-107, each targeting specific cancer mechanisms. The company's development approach combines ADC, IO, and mAb technologies to create innovative cancer treatments. The firm's pipeline focuses on improving patient outcomes through novel therapeutic approaches in oncology. Pyxis Oncology is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Pyxis Oncology's EBIT

Pyxis Oncology's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Pyxis Oncology's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Pyxis Oncology's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Pyxis Oncology’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Pyxis Oncology stock

EBIT of Pyxis Oncology is -84.42 M USD in 2025.

EBIT of Pyxis Oncology changed from -89.46 M USD to -84.42 M USD, representing a -5.63% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Pyxis Oncology since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Pyxis Oncology historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Pyxis Oncology

All Key Metrics — Pyxis Oncology